Secondary immunization with polysaccharide vaccines may imply a risk of hyporesponsiveness. Despite the wide use of typhoid Vi capsular polysaccharide vaccine, its potential tendency to hyporesponsiveness has been inadequately addressed. While previous studies have explored serum antibody responses, we applied a more sensitive approach, a single-cell assay for circulating plasmablasts, to compare primary and secondary responses. Twelve subjects received primary and booster doses of the Vi vaccine (Typherix â ) at 30-to 37-month intervals.
Introduction
The current typhoid vaccines, the parenteral capsular Vi polysaccharide vaccine (Typherix â or Typhim Vi â ) and the oral attenuated whole-cell Salmonella Typhi Ty21a preparation (Vivotif â ), have reached similar protection rates in field trials [1, 2] . They have different compositions, and therefore, the immunological mechanisms mediating protection differ. While the Ty21a vaccine induces both humoral and cell-mediated immune functions [3, 4] , the Vi as a polysaccharide (PS) vaccine is considered to confer protection by T cell-independent antibody production against the Vi antigen [1] . In contrast to oral vaccines, secondary immunization with polysaccharide (PS) vaccines has raised a concern for hyporesponsiveness, that is an immune response lower in magnitude than that after primary vaccination [5] . Despite the worldwide use of the Vi vaccine and the frequent need for booster immunizations, the question of hyporesponsiveness has not been adequately addressed.
The phenomenon of hyporesponsiveness has previously been demonstrated after meningococcal [5] [6] [7] and pneumococcal polysaccharide vaccines [5, 8] . PSs are considered T cell-independent antigens, as they are recognized by B cells but not presented to T cells. Without specific T cell interactions, no immunological memory is elicited and affinity maturation does not take place [5] . The mechanisms behind hyporesponsiveness are not known, but a number of hypotheses have been proposed, among them a depletion of the B memory cell pool resulting in an attenuated response to re-exposure to the same PS antigen [5] . Exposure to a large load of PS antigen in invasive pneumococcal disease has proved to cause immune paralysis to PS vaccine [9] , and studies with meningococcal PS vaccine have shown hyporesponsiveness to be dosedependent [7] . Even though typhoid fever poses a public health problem in large parts of the world, much less attention has been paid to the potential hyporesponsiveness after the typhoid Vi PS than pneumococcal and meningococcal vaccines. As far as we know, only one earlier investigation has been designed to primarily address the potential hyporesponsiveness after booster immunization with the Vi vaccine [10] , and a few others have provided data on antibody responses to a Vi booster dose [11] [12] [13] [14] [15] [16] .
Similarly to the Ty21a vaccine [17] [18] [19] , the Vi has recently been shown to elicit cross-reactive responses against the causative agents of paratyphoid fever [20] and several non-typhoid Salmonellae (NTS), including Salmonella enterica serotype Enteritidis and Typhimurium (S. Enteritidis and S. Typhimurium) [21] , the two most common causes of both diarrhoeal and invasive NTS diseases [22] . As all these strains are Vi-negative, the crossreactive responses have been ascribed to residual contaminating lipopolysaccharide (which contains typhoidal O-9,12) in the Vi vaccine preparation [23] . Consistently, the cross-reactive responses are significantly lower in magnitude after the Vi than the Ty21a vaccine [20, 21] . No data exist on cross-reactive responses after secondary immunization with the Vi vaccine.
Both serum antibodies [3, 24] and circulating plasmablasts [1, 3] have been suggested as laboratory correlates of protection. The latter represent recently activated endstage B cells trafficking from the site of antigen encounter via lymphatics and blood to their final effector sites [25] [26] [27] . Before homing to tissues as plasma cells, these plasmablasts can be captured transiently from the circulation for a period of approximately one week, peaking in magnitude on day seven [28] . A single-cell assay of plasmablasts has proved more sensitive than serum antibody assays [18, 28, 29] in measuring immune response to typhoid vaccines. Until this, studies of immune response to Vi vaccine boosting have examined serum antibodies [10] [11] [12] [13] [14] [15] , whereas no research has explored plasmablasts.
Applying a single-cell approach, this study set out to determine whether the Vi vaccine administered at the 3-year booster interval recommended by the manufacturer results in hyporesponsiveness. Both specific and crossreactive plasmablasts were examined.
Materials and methods
Study design. Twelve healthy volunteers received primary and booster doses of the Vi capsular polysaccharide vaccine (Typherix â ) at 30-37-month intervals. Primary immunization was initially given to 25 subjects whose results have been published earlier [20, 21, 23] . 12 of 25 vaccinees were available for booster immunization. We analysed circulating plasmablasts (1) specific to Vi antigen and (2) O-9,12 antigens and those cross-reactive with (3-5) Salmonella enterica serotype Paratyphi A/B/C (S. Paratyphi A/B/C), (6) S. Enteritidis and (7) S. Typhimurium. (8) Salmonella enterica serotype Hadar (S. Hadar) and (9) Yersinia enterocolitica served as negative controls. Plasmablasts were identified by enzyme-linked immunospot assay (ELISPOT) as antigen-specific antibody-secreting cells (ASC) (Fig. 1) s.a., Rixensart, Belgium, lot ATYPB096AF and ATYPB084BC with endotoxin contents of 13.30 and 27.00 EU, respectively, the latter used in both immunizations), at an interval of 30-37 months (median 34). The vaccine was administered as one 0.5 ml dose intramuscularly with a 25-mm needle on day 0. Blood samples were drawn on days 0 and 7 after vaccination.
ELISPOT assay of specific ASC and all ISC. The peripheral blood mononuclear cell (PBMC) was isolated by Ficoll-Paque centrifugation of fresh heparinized venous blood [28] and assayed for ASC using ELISPOT, as described earlier [18, 28, 30, 31] . The Vi antigen of the vaccine preparation (Typherix â , 10 lg/ml in phosphatebuffered saline) and six bacterial strains ( Statistics. The statistical analysis was conducted with SPSS 22 software (IBM Corp, Armonk, NY, USA). Wilcoxon signed-ranks test was used in comparison with primary and booster responses. Geometric means were given for each antigen (value zero replaced with 0.0001 to allow calculation of GeoMeans); 95% CIs were counted using bootstrapping.
Results

Adverse reactions
The vaccine was well tolerated. After primary vaccination, 1 of 12 subjects had mild pain at the injection site until the next day, and 1 of 12 reported constipation. After the booster dose, 2 of 12 had mild pain at the injection site until the next day. Table 1 Description of bacterial strains, specific and cross-reactive plasmablast responses. Data are given for bacterial strains a used in ELISPOT assay, O antigens of each strain, proportions of responders and numbers of antigen-specific antibody-secreting cells (ASC) in volunteers seven days after receiving primary or booster dose of Vi vaccine (geometric means of number of Ig(A + G + M)-ASC on day seven after vaccination; 95% CI counted using bootstrapping). Statistical comparisons were carried out by Wilcoxon signed-ranks test (two-tailed); differences between primary and booster dose were not significant with respect to any of the antigens. The zero values are replaced with value 0.00001 to allow the calculation for geometric means. The results of primary immunization have been presented previously as a part of the data of 25 subjects [20, 21, 23 On the day of primary and booster immunizations (day 0 for both), no Vi-or O-9,12-specific ASC were detected in the circulation of any of the vaccinees (Fig. 2) . After primary vaccination (day 7), all subjects had Vi antigenspecific ASC. The response after the Vi booster (day 7) was lower than after the primary dose for eight of 12 vaccinees (Fig. 3) , and four of these eight had a response that remained below the detection limit of the assay. All vaccinees showed ASC against the typhoidal O-9,12 antigen after both primary and booster immunizations. As for the O antigen-specific ASC, only two of 12 volunteers had a lower response to the booster than the primary dose (Figs 2 and 3) .
The geometric mean of the ASC (IgA + IgG + IgM)/ 10 6 PBMC specific to Vi antigen was 59 (95% CI 24-119) and 1 (0-54), and to O-9,12 antigen 20 (9-49) and 56 (29-103) after primary and booster immunization, respectively ( Fig. 3 and Table 1 ). The difference in the responses between primary and booster immunizations was not found statistically significant (Table 1) .
Cross-reactive ASC responses
None of the subjects showed cross-reactive ASC before the vaccinations (day 0), whereas after both immunizations (day 7), most of them had circulating plasmablasts crossreactive with strains sharing O or Vi antigen(s) with S. Typhi, that is to S. Paratyphi A, S. Paratyphi B and S. Paratyphi C (Table 1 and Fig. 4 ). All vaccinees responded to S. Enteritidis and most to S. Typhimurium (Table 1 and Fig. 5 ). After both primary and booster immunizations, one subject showed a minor response of <10 ASC/10 6 PBMC to S. Hadar (different individuals), which shares no O antigens with S. Typhi. None of the subjects had ASC against the negative control Yersinia enterocolitica.
A few vaccinees did not show cross-reactive responses to strains with O-12 after the first dose; the number of nonresponders was not greater after the secondary immunization (Figs 4 and 5 ). There were no statistically significant differences in the magnitude of cross-reactive response between primary versus booster immunization ( Table 1) .
Numbers of immunoglobulin-secreting cell (ISC)
ISCs represent the sum of all the ASCs present in the individual. In this study, ISCs have been measured as a positive control. The numbers of ISC did not differ between primary and secondary immunizations (P = 0.8365). The geometric mean and 95% CI of ISC response were 2320 IgA + IgG + IgM-ISC/10 6 PBMC (95% CI 1499-3775) after the first and 2037 (1322-3274) after the second dose. The low/absent responses to the Vi antigen appeared not to be reflected in the numbers of ISC (data not shown). This can be considered quite natural, for ISC response represents a total of all ASC responses to any antigens recently encountered, and lacking/low response to any single antigen is easily masked.
Discussion
Hyporesponsiveness has been raised as a concern when giving booster doses of PS vaccines, such as pneumococcal and meningococcal PS vaccines [5, 8] . The typhoid Vi PS vaccine has got much less attention than the other two; the only data available on the Vi vaccine concerns serum antibody responses. The present study is the first to explore the potential hyporesponsiveness by looking at plasmablasts after secondary immunization with the Vi vaccine.
Our single-cell assay revealed that while a response to the Vi antigen was shown by all subjects after the primary immunization, four of 12 of them totally failed to respond to the booster dose. The data suggest hyporesponsiveness to the Vi PS, but only for part of the vaccinees. The finding deserves a critical discussion, which will follow below.
Firstly, the numerical data of the secondary response to Vi antigen varied between individuals: while four of 12 subjects showed no response, four of 12 had a lower, and four of 12 a similar or even higher response than that after primary immunization. Further research is needed to show whether our findings simply reflect different types of immune responses in various individuals or if, in fact, part of the vaccinees had already recovered from the immune paralysis and got a reasonable response, while for others, the 30-to 37-month interval would have been too short.
Secondly, the difference is apparently not methodological as both low and high responses were measured at the same time. Moreover, simultaneously, we measured high responses to primary immunization for volunteers from another study (data not shown here) [32] .
Thirdly, it appears illogical that the individuals lacking a response to Vi antigen exhibit a simultaneous response to O antigens, which also are polysaccharide structures. However, the O antigen (part of the contaminating LPS) in the Vi vaccine may not appear in the Vi vaccine as a .......................................................................................................................................................... ..... purified polysaccharide structure, but linked to other molecules. In our previous study [33] , exploring responses to primary and secondary parenteral whole-cell typhoid vaccination, eight of nine vaccinees responded to the O antigen after primary and seven of eight after secondary immunization (data not shown). In both the former study and the present one, our assay may have failed to detect hyporesponsiveness, for our whole-cell preparates used as antigens in the ELISPOT may contain some other, minor antigens. Although responses to such antigens are presumed to be very low, they might mask the lack of response in some individuals.
Fourthly, while in some studies, the plasmablast response has peaked on day 7 after booster [28, 30, [34] [35] [36] [37] [38] ; in others, the peak has been seen on day 5 [39] [40] [41] . As only one could be chosen, we selected day 7, as the Vi polysaccharide is presumed to elicit a T cell-independent antibody production, and accordingly, one should not expect it to follow an accelerated kinetics similar to that of vaccines which induce memory and booster response [39] [40] [41] .
The geometric mean of the number of Vi-specific plasmablasts appeared lower after the booster (1; 95%CI 0-54) than after primary immunization (59; 95% CI 24-119), yet the difference did not reach statistical significance. This is readily explained by interindividual variation: as part of the vaccinees responded well, hyporesponsiveness in others may not have been revealed. Likewise, in studies exploring GMTs of serum antibodies, possible non-responders may not have been identified, but they could have been reflected as a decrease in the GMT. Indeed, although perhaps not statistically significant, in several reports, the numerical GMTs have been lower after the booster than the primary dose (see below) [10, [12] [13] [14] [15] .
While the present study is the first to explore hyporesponsiveness at a single-cell level, ten earlier investigations have examined serum antibodies after booster immunization [10] [11] [12] [13] [14] [15] [16] [42] [43] [44] , seven of them in humans [10] [11] [12] [13] [14] [15] [16] . Four of the seven human studies include data which suggest some degree of hyporesponsiveness [12] [13] [14] [15] , and one of them does not exclude it [10] . Only Keitel et al. and Moore et al. found similar serum Viantibody levels after primary and booster immunization: Keitel et al. [11] reported geometric mean concentrations (GMC) of 3.2-3.6 lg/ml (n = 182) after primary and 3.0 or 3.3 lg/ml after secondary dose given 27 (n = 43) or 34 months apart (n = 12), respectively. Moore et al. [16] found GMTs at 5.94 EU after primary (n = 245) and 5.10 EU after booster immunization (n = 217) 2 years later. In contrast to these reports, Lebacq et al. reported anti-Vi PS GMTs at 1312 (95% CI 1133-1415) after primary immunization with Typherix (n = 300) and 849 (678-1063) after the 1-year booster (n = 149), and 1000 (796-1256) after the 2-year booster (n = 145). These data attest to hyporesponsiveness at least among those boosted at 1 year. It has been speculated that some degree of recovery from immune paralysis over 2 years could account for the titres being numerically higher after the 2-year than the 1-year booster. Overbosch et al. immunized volunteers concomitantly with a hepatitis A and a Vi vaccine and boosted them 3 years later with a hepatitis A + Vi combination preparation (Viatim). They reported GMTs of 2.72 (95% CI 2.31-3.02) after primary (n = 179) and 1.81 (1.24-2.65) (n = 43) after secondary immunization, suggestive of hyporesponsiveness to the Vi component despite a simultaneous enhanced response to the hepatitis A component [13] . Zhou et al. [14] immunized 58 children 3 years apart. The GMTs proved lower after the booster (29.3 AE 3.6) than the primary dose (39.5 AE 4.2), but the difference did not reach statistical significance [14] . Bhutta et al. [15] explored a Vi conjugate vaccine in children and had Vi PS together with PCV12 vaccine as a comparator (n = 38). The Vi-antibody titres were somewhat lower after the second dose given at a 2-month interval, yet statistical analyses were not included [15] . Recently, in the sole study primarily designed to explore hyporesponsiveness, Roggelin et al. had 85 subjects divided into two groups, 40 vaccinated for the first time and 45 who had earlier got one or more booster doses. They found neither hyporesponsiveness nor a booster effect 18-57 (median 38) months after the last vaccination [10] . The GMT of Vispecific antibodies was 11.34 (7.20-15.49 ) lg/ml after primary vaccination (n = 40), 16.10 (8.56-23.63 ) after the first booster dose (n = 36) and 8.49 (3.79-13.19 ) after a boosting of subjects having previously received two or more doses (n = 9). The responses to the subsequent booster doses appeared to be lower than those to the first booster, yet did not reach statistical significance [10] . Interestingly, they published a graph showing individual responses: a few volunteers proved non-responders after the secondary dose.
Besides antigen load [7, 45] , administration route and boosting interval contribute remarkably to hyporesponsiveness. While 50-500-lg parenteral injection of pneumococcal PS leads to immune paralysis, no hyporesponsiveness is seen even after large orally administered doses [46] . Likewise, enhanced immune response has been reported after an oral booster dose of the Ty21a vaccine given 1-2 years apart [33, 39] and rectal boosting 6 months apart [47] . When using parenteral vaccines, the period of time between immunizations matters [46] : the longer the interval, the less likely the hyporesponsiveness [8] . Also, in the study by Lebacq et al. [12] , the responses to a second Vi dose appeared higher among those boosted after two than after 1 year. In the investigation by Roggelin et al. [10] , the interval did not seem to have an impact, yet the primary and booster responses were not explored for the same individuals.
The main limitation of the present study is that only 12 of the 25 vaccinees of our previous investigation [20, 21, 23] could be recruited. However, as ESLIPOT as a singlecell assay is known to be particularly sensitive, plasmablast studies conducted even with small subject groups are generally considered reliable [48] . We could not measure serum antibodies, but previous investigations of typhoid vaccines have shown ELISPOT to be substantially more sensitive than assays for serum antibodies or antibodies in lymphocyte culture supernatants (ALS) [18, 28, 29] . The same individuals were examined after both primary and secondary immunization, which further improves the reliability of our findings, allowing interindividual differences to be ignored.
The definition of hyporesponsiveness includes a failure to produce a similar or enhanced response compared to that after primary immunization [5] . The results of our study and those listed above may not be conclusive, yet none of them reports a booster effect after the second Vi dose. Many studies with serum antibodies either suggest hyporesponsiveness [12] [13] [14] or cannot exclude it [10, 15] . The differing results agree with our plasmablast data showing hyporesponsiveness or lack of response for part of the vaccinees, and normal responses for others.
Although the clinical implications of hyporesponsiveness have not been extensively studied, there is at least a theoretical risk of increased disease susceptibility [5] . However, the majority of vaccinees have been reported to reach protective serum antibody levels after the booster Vi dose [10] [11] [12] [13] [14] [15] , suggesting that secondary immunization with this vaccine is warranted. On the other hand, as the present study indicates that hyporesponsiveness may be induced in part of the vaccinees, it seems reasonable to use the oral Ty1a vaccine for boosting, if available, as it is not associated with hyporesponsiveness. It may, as proposed by cross-protection and cross-reactivity studies, even offer the benefit of protection against paratyphoid strains [17, 19, [49] [50] [51] [52] [53] [54] [55] and some NTS [18] . Of course, should the protection afforded by the Vi vaccine be partly mediated by the contaminating LPS [23] , the concern of hyporesponsiveness to the Vi component would be less alarming.
Conclusions
A single-cell analysis showed both typhoid-specific (Viand O-9,12-antigen) and cross-reactive (both paratyphoid and NTS strains) plasmablasts after primary immunization with the Vi vaccine. Secondary responses to typhoid O antigen and cross-reactive strains did not differ from these. As for the Vi antigen, concurring with many previous studies of serum antibodies, the booster response was numerically lower, but the difference not statistically significant. However, an individual analysis at the singlecell level revealed that one-third of the subjects, while responding to the O antigen, failed to respond to the Vi antigen after secondary immunization. This implies that hyporesponsiveness to Vi polysaccharide is elicited in a number of vaccinees.
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